ArticleKidney medicine2026
Atypical Hemolytic Uremic Syndrome Associated With Malignant Hypertension Presenting With Pulmonary-Renal Syndrome-like Symptoms.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both atypical hemolytic uremic syndrome (aHUS) and malignant hypertension (MHT) are causes of thrombotic microangiopathy (TMA), and their coexistence has been reported. We describe a 22-year-old man who exhibited severe hypertension, pulmonary hemorrhage, and acute kidney injury. Laboratory evaluation revealed thrombocytopenia, microangiopathic hemolytic anemia, and severe kidney dysfunction, without evidence of retinal hemorrhage or renal artery stenosis. Given suspicion for MHT-related thrombotic microangiopathy or immune-mediated pulmonary-renal syndrome, antihypertensive therapy, continuous hemodiafiltration, corticosteroids, and plasma exchange were initiated. However, autoimmune serologic testing was negative, von Willebrand factor protease (ADAMTS13) activity was preserved without inhibitor, and stool cultures were negative, leading to discontinuation of plasma exchange and tapering of corticosteroids. Thereafter, hematologic abnormalities transiently improved, but kidney dysfunction persisted, and pulmonary hemorrhage and cytopenia recurred with a marked reduction in complement C3 despite stabilized blood pressure reduction. Plasma exchange was resumed, and ravulizumab was initiated. Kidney biopsy demonstrated ischemic glomerular changes without immune deposits and marked narrowing of the interlobar arteries. Although genetic analysis identified variants in complement-related genes, definitive causative abnormalities remained undetermined. The patient was discharged with recovered kidney function, normalization of complement proteins, and sustained hematologic remission. Collectively, this clinical course is compatible with aHUS. We consider that MHT might trigger overt aHUS with pulmonary-renal syndrome-like features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.